{"title": "PDF", "author": "PDF", "url": "medialibrary.uantwerpen.be/oldcontent/container39248/files/ANT102_TINO%20SCHWARZ_Antwerp_HPV_14Nov2019_final.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "15-55: Study findings and way forward Tino F. Schwarz Institute from GSK and PfizerMethods Study design: (10 -year) follow -up study (HPV -014 EXT; NCT00947115) of a (HPV -014; NCT00196937) Participants: women aged 15 -55 years at the time of vaccination who received 3 doses of AS04 -HPV -16/18 Vaccine (at months 0, 1, 6) in HPV -014; study sites in Germany and Poland cervico -vaginal secretions (CVS) by enzyme -linked immunosorbent assay (ELISA) Samples were collected at years 5, 6, 7, 8, 9, 10 Safety was assessed throughout the study Analyses: participants were stratified by age at vaccination: 15 -25, 26-45, 46-55 years PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 -ADJUVANTED TF -2731 (2017)Seropositivity rates in serum at Year 10 Age cut -off* for (Year 10 ATP cohort for immunogenicity) PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 - ADJUVANTED interval; VLP, virus -like particleAntibody Levels in 15 -55 Year Olds Comparable to those Observed in Efficacy Study HPV -001/007 Assay cut -off: 8 EU/mlATP analysis Seronegative prior 18 39-44 yearsAt least 8-fold higher than natural infection 46-55 years Harper DM et al. Lancet 2006; Paavonen J et al. S. Levels in 15 -55 Year Olds Comparable to those Observed in Efficacy Study HPV -001/007 Assay cut -off: 7 EU/ml Harper DM et et vaccination15-25 years Efficacy studyHPV -18 At least higher VLP IgG GMTs in serum 110100100010000 0 1 2 3 4 5 6 7 8 9 10HPV -16 GMT (EL.U/mL) (95% CI) years 46-55 yearsIn initially seronegative women (Year 10 ATP cohort for immunogenicity) PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 - ADJUVANTED TF (95% CI 802 -1162) 271 -414) 157 (95% CI 128 -193) Plateau level1 Natural infection Hum Vaccin Immunother GMTs in serum 110100100010000 0 1 2 3 4 5 6 7 8 9 10HPV -18 GMT (EL.U/mL) (95% CI) years 46-55 yearsIn initially seronegative women (Year 10 ATP cohort for immunogenicity) PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 - ADJUVANTED VACCINE TO -55 YEARS EUROGIN 2016 ; Schwarz TF et al. Cancer 6:2723 (2017)Year 10 (95% CI 265 -389) 115 (95% CI 94 -142) 70 (95% CI 56 -87) Plateau level1 Natural infection level2 1. Naud PS, et al. Hum Vaccin Immunother J serum and CVS anti-HPV -16/18 antibodies * Standardised for total IgG (Year 10 TVC) PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 - ADJUVANTED VACCINE -55 YEARS EUROGIN 2016 power %100% 95.7 . 2014;10(12):3435 cohort = sub -cohort of the M60 according -to-protocol cohort for immunogenicity that includes seronegative and DNA -nega tive subjects at baseline with available and valid results for the HPV type analysed at each time point. ED50 = serum dilution giving a 50% reduction of the signal compared with a control. PBNA , pseudovirion -based for HPV -16 and -18 al. , Hum Vacc 2009; -6/11/16/18 y HPV -6/11/16/18 vaccine 36 -45 y1101001000100001000001000000 0 6 12 18 24 30 36 42 48 54 601101001000100001000001000000 0 6 12 18 24 30 36 42 48 54 60Safety during the entire 10 -year study period Year 10 TVC Fatal adverse events -1 chronic lymphocytic leukaemia (considered not vaccine related) -1 malignant lung neoplasm (considered not vaccine related) Serious adverse events considered related to vaccine -1 cervical dysplasia at Year 8 (subject was HPV -16 seropositive and unknown DNA status before vaccination). The subject recovered PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 - ADJUVANTED VACCINE -55 YEARS EUROGIN 2016 Schwarz TF et Immunogenicity those aged 15-25years, similar toorabove theplateau level observed in studies where vaccine efficacy was demonstrated inthose aged 15-25years Among the older age groups, similar toorbelow this plateau level above natural infection levels (as determined inunvaccinated women who had cleared an infection ) Good correlation between antibodies (IgG) intheserum and intheCVS sustained uptoMonth 603 1. PERSISTENCE OF IMMUNE RESPONSE 10 YEARS AFTER ADMINISTRATION OF THE HUMAN PAPILLOMAVIRUS (HPV) -16/18 AS04 -ADJUVANTED VACCINE Schwarz TF et al. Cancer Med 6:2723 -2731 (2017 ); Einstein MH et al. Hum Vaccin Immunother . 2014;10(12):3435 -45. "}